Drug Database
FA

Factor VIII

✓ Approved

Quimbiotec · F8 · Cell-based Therapies

What is Factor VIII?

Factor VIII is a cell-based therapies developed by Quimbiotec. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyQuimbiotec
Drug ClassCell-based Therapies
Molecular TargetF8
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Mechanism of Action

Molecular Targets

Factor VIII acts on 1 molecular target:

F8coagulation factor VIII (AHF, FVIII)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

Factor VIII is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersFactor VIII deficiency✓ Approved

Related Research Articles

PubMedNursing & health sciences2026-07-17

Risk Stratification and Nursing Strategy for Recurrent Readmission in Primary Venous Thromboembolism: A Study Based on NT-proBNP and Factor VIII.

Wang Xia X, Li Jia J, Yu Ying Y, Zhang Shujin S et al.

To identify factors influencing recurrent readmission in patients diagnosed with Venous thromboembolism (VTE) who underwent interventional or surgical procedures and propose an evidence-based nursing strategy. This retrospective cohort study included 121 patients with VTE admitted to Shanxi Bethune Hospital (February 2022-February 2025). Patients were divided into recurrence and non-recurrence groups based on readmission. Independent predictors were identified using logistic regression. Model performance was assessed by ROC curves, nomograms, and calibration plots. Recurrent readmission occurred in 24 patients (19.83%). Independent predictors included BMI (OR = 1.625), NT-proBNP (OR = 1.014), factor VIII (OR = 1.032), MMAS-8 (OR = 0.587), and AHSMSRS scores (OR = 0.950). The combined model showed excellent predictive accuracy (AUC = 0.849; 95% CI: 0.767-0.930), with good calibration. Elevated BMI, NT-proBNP, and factor VIII, along with poor medication adherence and self-management, predict VTE recurrence. Early identification and targeted nursing interventions may reduce readmission rates.

PubMedSage open pediatrics2026-07-17

Hemophilia and Type 1 Diabetes in a Pediatric Patient: Case Report of an Extremely Rare Association.

Virú-Loza Manuel André MA

Reports on the association between hemophilia and pediatric diabetes are very scarce in the literature, with no more than four worldwide. This report describes the case of a 14-year-old male with severe hemophilia A and type 1 diabetes who was brought to the emergency department due to fever and bruising on his back and jaw following trauma. The patient responded well to plasma-derived factor VIII, drainage, antibiotic therapy, and management with NPH and Regular insulin. There were no problems with the use of subcutaneous insulins during hospitalization. Previously reported cases in the literature describe potential bleeding and bruising associated with devices used for managing pediatric diabetes. However, severe bleeding and bruising that significantly impede diabetes treatment do not appear to be present, although individualized management is still required.

PubMedbioRxiv : the preprint server for biology2026-07-17

AAV VP1 unique region (VP1u) determines GPR108 dependence for AAV transduction of human airway epithelium and its rescue by Doxorubicin.

Hao Siyuan S, Habib Ariful A, Zhang Xiujuan X, Ning Kang K et al.

rAAV2.5T was identified through directed evolution of an AAV capsid library in polarized human airway epithelium (HAE) cultured at an air-liquid interface (ALI). The capsid gene of rAAV2.5T is a chimera of the N-terminal unique region of AAV2 VP1 (VP1u) and the VP2 and VP3 regions of AAV5 with a single A581T substitution at the variable region (VR) VIII of the capsids. GPR108, a G protein-coupled receptor, is known as an essential host factor for the transduction of rAAV2 but not of rAAV5. Both AAV2 and AAV5 VP1u colocalized well with GPR108 and, to a lesser extent, with the trans -Golgi network (TGN). GPR108 knockout (KO) abolished rAAV2.5T transduction in both HeLa cells and HAE-ALI cultures. Remarkably, short-term treatment with doxorubicin (DOX) at 2 µM completely restored transduction, indicating that DOX can compensate for the loss of GPR108 function. DOX enhanced rAAV2.5T transduction by 50-100-fold in wild-type HAE-ALI cultures and by over 300-fold in the GPR108-deficient cultures. Mechanistic studies demonstrated that this enhancement resulted from altered intracellular trafficking that promoted efficient vector nuclear import, rather than increased vector internalization, proteasome inhibition, or activation of the DNA damage response. Importantly, we identified that the N-terminal 15 amino acids of AAV2 VP1u as the primary determinant of rAAV2.5T dependence on GPR108 for transduction. Collectively, these findings demonstrate that productive transduction of rAAV2.5T in polarized HAE cultures depends on GPR108-mediated intracellular trafficking that limits efficient nuclear entry, and that DOX can relieve this constraint by promoting efficient vector import. AAV2.5T is an airway-tropic vector with considerable promise for pulmonary gene therapy. We found that host factor GPR108 is required for rAAV2.5T trafficking from the TGN to the nucleus and that this step constitutes a major bottleneck to productive transduction in polarized HAE. In contrast, KIAA0319L (AAVR) plays a key role in AAV intracellular trafficking from the endosome to the TGN but not in internalization into polarized HAE during apical transduction. Transient treatment with low-dose doxorubicin (DOX, 2 µM) enhanced rAAV2.5T transduction in HAE by 50-100-fold through a significant increase in vector nuclear import. Notably, DOX can overcome the transduction deficit caused by GPR108 deficiency, but not that caused by AAVR deficiency. Mechanistically, the N-terminal 15 amino acids of the VP1u confer GPR108 dependence during rAAV2.5T apical transduction of polarized HAE. DOX bypasses this requirement by promoting efficient nuclear import without affecting vector internalization, inhibiting proteasomes, or inducing DNA damage response.

PubMedFrontiers in bioinformatics2026-07-17

Correction: Unraveling the molecular basis of snake venom nerve growth factor: human TrkA recognition through molecular dynamics simulation and comparison with human nerve growth factor.

Devi Shrudhi S, Jayaraman Gurunathan G

[This corrects the article DOI: 10.3389/fbinf.2025.1674791.].

PubMedBritish journal of haematology2026-07-17

In a nutshell: Explaining joint and muscle bleeding in individuals with haemophilia A and B.

Lau Benjamin K BK, Srivatsa Shantanu S, Mackman Nigel N

(A) Formation of the platelet-fibrin haemostatic plug. Vascular injury exposes von Willebrand factor (VWF) and tissue factor (TF) to flowing blood. VWF mediates platelet adhesion, leading to platelet activation and aggregation, while TF triggers the coagulation cascade, generating thrombin that converts fibrinogen to fibrin. Thrombin also amplifies platelet activation, integrating the two arms so that platelet aggregates and a fibrin mesh combine to form a stable platelet-fibrin haemostatic plug. (B) Anatomical correlation between bleeding phenotype and tissue factor expression. Typical bleeding sites in haemophilia A and B (intra-articular and intramuscular) are shown relative to the tissue-specific pattern of high tissue factor (TF) expression. Vital organs such as the brain, heart and lungs exhibit high TF expression, proposed to provide additional haemostatic protection, whereas the low TF expression in joints and skeletal muscle leaves these sites more reliant on FVIII- and FIX-dependent amplification and therefore vulnerable to bleeding when these factors are deficient. Figure created with BioRender.com.

PubMedBrain and behavior2026-07-17

The Validation of the Revised Illness Perception Questionnaire in Cancer Patients: An Exploratory Factor Analysis for Further Psychometric Evidence.

Fasakhoudi Maryam Amini MA, Karsazi Hossein H, Shahi Asma A, Beyraghdar Narin N et al.

Applying the Leventhal's model would make it possible to highlight the cognitive and emotional representations of adults with cancer and then to propose specific interventions to improve their adherence. This paper was conducted aiming at the validation of the revised illness perception questionnaire (IPQ-R) based on an exploratory factor analysis (EFA) in cancer patients. The IPQ-R was administered to 300 outpatients referred during a 9 months period. In the present study, we performed an EFA to examine the construct validity of the instrument. In addition, the concurrent validity of the IPQ-R with the positive and negative affect schedule, depression, anxiety and stress scale- 21 items and 36-item Short-Form Health Survey questionnaires was evaluated. Reliability was calculated using Cronbach's alpha, McDonald's omega, and test-retest methods. EFA of the beliefs and causes subscales revealed seven dimensions and three factors, respectively. With the difference that in the causes subscale, instead of the four factors of the original study, three factors were extracted. The validity and reliability of the identity subscales and beliefs overall were rated as good to excellent, but the concurrent validity of the Causes subscale was in the factor of psychological attributions and risk factor high and low, respectively, and for the substance use factor, it also did not obtain any correlation. For reliability, the risk factors received a low score. Adaptation of the IPQ-R in Iranian culture and an adult population suffering from cancer disease made it possible to use it for this particular population.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Factor VIII